PMGC Holdings Inc. (ELAB)
D
Pipeline Grade
Financial Position (from SEC Filings)
$14.4M
Cash & Equivalents
$3.0M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$5M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06626308 | Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study | OTHER | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-01 | 8-K | PMGC Holdings Inc. (ELAB) (CIK 0001840563) - PRESS RELEASE DATED JULY 1, 2026 | EDGAR |